Primary Immunodeficiency Disease
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Octapharma16,5% Cutaquig
TakedaIGSC 20% infusion
Biotest PharmaceuticalsIgG Next Generation
OctapharmaNewGam
Clinical Trials (4)
Total enrollment: 63 patients across 4 trials
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
Start: Sep 2018Est. completion: Aug 202130 patients
Phase 4Unknown
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
Start: Apr 2021Est. completion: Apr 202412 patients
Phase 3Completed
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Start: Oct 2016Est. completion: Apr 2020
Phase 3Completed
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
Start: May 2011Est. completion: Sep 201221 patients
Phase 3Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space